TREAT-GNB Phase 4 Trial Evaluating Antibiotic Treatments for Severe Carbapenem-Resistant Gram-Negative Bacterial Infections in Bloodstream and Lung
Led by National University of Singapore · Updated on 2025-06-04
600
Participants Needed
41
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating various antibiotic treatments for severe multidrug-resistant Gram-negative bacterial infections, focusing on bloodstream infections, ventilator-associated pneumonia, and hospital-acquired pneumonia caused by carbapenem-resistant Gram-negative bacteria. This innovative platform trial uses adaptive clinical designs to speed up assessment and optimize resources, aiming to find interventions that improve survival in these serious infections.
The study compares multiple antibiotic regimens, including combinations like ColistinPolymyxin B with Sulbactam or TigecyclineEravacycline, Ceftazidime-avibactam alone or combined with other drugs, high-dose meropenem, and others. These treatments are given intravenously to patients with confirmed infections caused by resistant bacteria, with random assignment to different treatment groups. The trial includes a primary phase evaluating outcomes at 28 days post-randomisation.
Participants will be monitored closely with clinical assessments at multiple time points, including 14, 28, 60, and 90 days after randomisation. Researchers will track all-cause mortality and other clinical outcomes to evaluate the effectiveness of each treatment. Safety and health economics outcomes will also be recorded. The study is led by the National University of Singapore and plans to run until the end of 2028.
CONDITIONS
Brief Title
Optimising TREATment for Severe Gram-Negative Bacterial Infections
Research Team
Y
Yin Mo, MBBS, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with bloodstream infections caused by Gram-negative bacilli confirmed by blood culture
Diagnosed with ventilator-associated or hospital-acquired pneumonia meeting CDC infection syndrome definitions
Suitable for at least two antibiotic regimens listed for randomisation at the study site
Receiving or planning to receive intravenous antibiotics
Expected time from culture sampling to randomisation is 96 hours or less
Infection caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, Pseudomonas aeruginosa, or Enterobacterales confirmed phenotypically or genotypically
You will not qualify if you...
Treating team considers study enrolment not in the patient's best interest
Patient is receiving end-of-life care
Patient is incarcerated in a correctional facility
Participation in any interventional study activities within the TREAT-GNB study in the last 90 days
Pregnant women and children
Presence of polymicrobial bloodstream infection
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 28 days post-randomisation
Participants receive assigned antibiotic regimens to treat severe Gram-negative bacterial infections caused by carbapenem-resistant organisms.
Visits occur during treatment as per clinical care; frequency varies by site
Follow-up
Duration - Up to 90 days post-randomisation
Participants are monitored for clinical outcomes and health status at multiple time points after treatment ends.
Follow-up visits at approximately 14, 28, 60, and 90 days post-randomisation
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
14
Similar Trials
Personalized Versus Standard Duration of Antibiotic Therapy in High-Risk Febrile Neutropenia Patients
Evaluating Clinical Stability-Driven Treatment and Outcomes in Bloodstream Infection
Comparison of Cefiderocol Plus Ampicillin-sulbactam Versus Colistin With or Without Meropenem for Treating Carbapenem-Resistant Acinetobacter Baumannii Bloodstream and Lung Infections
Tracking Antibiotic Resistance in Bacterial Infections for Patients with Cirrhosis in Latin America
Observational Study of Bloodstream Infections in Adults with Hematological Malignancies and Stem Cell Transplants Across the Middle East
TREAT-GNB Phase 4 Trial Evaluating Antibiotic Treatments for Severe Carbapenem-Resistant Gram-Negative Bacterial Infections in Bloodstream and Lung
Early Oral Antibiotic Switch Compared to Standard Intravenous Therapy in Children and Adolescents with Bloodstream Infections
Real-World Study of Sulbactam-Durlobactam for Treating Carbapenem-Resistant Acinetobacter Baumannii Infections
Effectiveness, Safety, and Drug Exposure Analysis in Hospitalized Adults
Impact of Rapid Antimicrobial Sensitivity Testing on Antibiotic Use and Outcomes in Bloodstream Infection Patients A Randomized Adaptive Trial